Get notified when NRXP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Both auditors included a going-concern explanatory paragraph, indicating substantial doubt about the company's ability to continue operating.
NRX Pharmaceuticals prices $20M offering of 5.7M shares at $3.50 each
Filed June 3, 2026 · ~1 min read
Key Changes
-
high
NRX Pharmaceuticals is selling 5,714,286 shares at $3.50 per share, raising $20.0M gross; net proceeds to the company are $18.8M.
The Offering verify on EDGAR → -
medium
The company plans to use net proceeds for working capital and general corporate purposes, with no specific allocation.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $3.44 per share, as pro forma net tangible book value is only $0.06 per share after the offering.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (GIS 10-Q) is open in full — no account needed.
Partner
Trade NRXP commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify